Research programme: gene therapies - CANbridge Pharmaceuticals/University of Washington School of Medicine
Latest Information Update: 24 Mar 2022
At a glance
- Originator University of Washington
- Developer CANbridge Pharmaceuticals; University of Washington
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Duchenne muscular dystrophy
Most Recent Events
- 22 Mar 2022 CANbridge Pharmaceuticals intends to announce pre-clinical lead candidate in Duchenne muscular dystrophy, in 2023
- 01 Nov 2021 CANbridge Pharmaceuticals and University of Washington School of Medicine agree to develop gene therapies for Duchenne muscular dystrophy
- 01 Nov 2021 Early research in Duchenne muscular dystrophy in USA (Parenteral)